What is "resistance" in Paget's disease of bone?

Arthritis and Rheumatism

Volumn 48, Issue 8, 2003, Pages 2097-2099

  Lyles, Kenneth W ^a  

^a DUKE UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALENDRONIC ACID; ALKALINE PHOSPHATASE; BISPHOSPHONIC ACID DERIVATIVE; CLODRONIC ACID; ETIDRONIC ACID; GERANYLTRANSFERASE; GUANINE NUCLEOTIDE BINDING PROTEIN; PAMIDRONIC ACID; PYROPHOSPHATE; RISEDRONIC ACID; SALCATONIN; TILUDRONIC ACID; ZOLEDRONIC ACID;

ALKALINE PHOSPHATASE BLOOD LEVEL; BONE REMODELING; BONE TURNOVER; DISABILITY; DRUG EFFICACY; EDITORIAL; ENVIRONMENTAL FACTOR; FAMILY HISTORY; FUNCTIONAL DISEASE; HEREDITY; HUMAN; OSTEOBLAST; PAGET BONE DISEASE; PRENYLATION; PREVALENCE; PRIORITY JOURNAL;

DIPHOSPHONATES; DRUG RESISTANCE; HUMANS; OSTEITIS DEFORMANS;

EID: 0042574048     PISSN: 00043591     EISSN: None     Source Type: Journal    
DOI: 10.1002/art.11135     Document Type: Editorial

References (15)

1. Joshua F, Epstein M, Major G. Bisphosphonate resistance in Paget's disease. Arthritis Rheum 2003;48:2321-3.
2. Delmas PD, Meunier PJ. The management of Paget's disease of bone. N Engl J Med 1997;334:558-66.
3. Van Staa TP, Selby P, Leufkens HG, Lyles K, Sprafka JM, Cooper C. Incidence and natural history of Paget's disease of bone in England and Wales. J Bone Miner Res 2002;17:465-71.
4. Cundy T, McAnulty K, Wattie D, Gamble G, Rutland M, Ibbertson HK. Evidence for secular change in Paget's disease. Bone 1997;20:60-71.
5. Morales Piga AA, Bachiller-Corral FJ, Abraira V, Beltran J, Rapado A. Is clinical expression of Paget's disease of bone decreasing? Bone 2002;30:399-403.
6. Cooper C, Schafheutle K, Dennison E, Kellingray S, Guyer P, Barker D. The epidemiology of Paget's disease in Britain: is the prevalence decreasing? J Bone Miner Res 1999;14:192-7.
7. Reddy SV, Singer FR, Roodman GD. Bone marrow mononuclear cells from patients with Paget's disease contain measles virus nucleocapsid messenger ribonucleic acid that has mutations in a specific region of the sequence. J Clin Endocrinol Metab 1995;80:2108-11.
8. Gordon MT, Anderson DC, Sharpe PT. Canine distemper virus localized in bone cells of patients with Paget's disease. Bone 1991;12:195-201.
9. Helfrich MJ, Hobson RP, Grabowski PS, Zurbriggen A, Cosby SL, Dickson GR, et al. A negative search for a paramyxoviral etiology of Paget's disease: molecular immunological and ultrastructural studies in UK patients. J Bone Miner Res 2000;15:2315-29.
10. Rima BK, Gasson U, Helfrich MH, Raston SH. The pro and con of measles virus in Paget's disease: con [letter]. J Bone Miner Res 2002;17:2290-2.
11. Friedrichs WE, Reddy SV, Singer FR, Roodman GD. The pro and con of measles virus in Paget's disease: pro [letter]. J Bone Miner Res 2002;17:2293.
12. Morales-Piga AA, Rey-Rey JS, Corres-Gonzalez J, Garcia-Sagredo JM, Lopez-Abente G. Frequency and characteristics of familial aggregation of Paget's disease of bone. J Bone Miner Res 1995;10:663-70.
13. Laurin N, Brown JP, Lemainque A, Duchesne A, Huot D, Lacourciere Y, et al. Paget's disease of bone mapping of two loci at 5q35-qter an 5q31. Am J Hum Genet 2001;69:528-43.
14. Kanis JA. Pathophysiology and treatment of Paget's disease of bone. 2nd ed. London: Martin Dunitz; 1998; p. 159-220.
15. Miller DP, Brown JP, Siris ES, Hoseyni MS, Axelrod DW, Bekker PJ. A randomized, double-blind comparison of risedronate and etidronate in the treatment of Paget's disease of bone. Am J Med 1999;106:513-20.